Table 2. Summary of model projections after following the recommended guidelines set by WHO and suggestions for programmatic adaptations in cases where the WHO goals are not achieved for S. haematobium (no acquired immunity is assumed) [12].

Baseline prevalence in SAC	Morbidity goal reached?	EPHP goal reached?	Programmatic adaptation
Low (< 10%)	Yes, within 3 years	Yes, within 15 years	NA
Moderate (47%)	Yes, within 11 years	Not reached	Include adult treatment at 40% coverage
High (≥ 50%)	Yes, within 15 years	Not reached	Increase coverage to 85% for SAC and include adult treatment at 40% coverage

β₀₋₄ = 0.17, β₅₋₁₁ = 1, β₁₂₋₂₀ = 0.11, β₂₁₊ = 0.035 are estimated by fitting the model to intensity data for S.haematobium (data from Misungwi area (Tanzania).